Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	2

65. Primary immunodeficiency

---

Clinical trials : 500 /  Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00389324 (ClinicalTrials.gov)	November 2006	17/10/2006	A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency	An Open-Label Single-Sequence, Crossover Trial to Evaluate the Pharmacokinetics and Safety of Subcutaneous Gamunex® 10% (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) in Subjects With Primary Immunodeficiency	Immunologic Deficiency Syndrome	Biological: Immune Globulin Intravenous (Human)	Grifols Therapeutics Inc.	NULL	Completed	13 Years	75 Years	All	35	Phase 2	United States;Canada
2	NCT00220766 (ClinicalTrials.gov)	August 2002	13/9/2005	Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients	IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients	Immunologic Deficiency Syndrome;Agammaglobulinemia;Severe Combined Immunodeficiency;Wiskott-Aldrich Syndrome;Common Variable Immunodeficiency	Drug: Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Drug: Dextrose, 5% in Water	Grifols Therapeutics Inc.	NULL	Completed	18 Years	75 Years	Both	100	Phase 3	United States;Canada